{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:33:15Z","timestamp":1787063595644,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.rpth.2024.102470","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:56:24Z","timestamp":1717851384000},"page":"102470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interference of lupus anticoagulant causing antiprothrombin and anti\u2013beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9077-5737","authenticated-orcid":false,"given":"Rachel","family":"Gehlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne G.","family":"Moesbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CuiCui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.Gerard","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost C.M.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"de Laat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper A.","family":"Remijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102470_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0037-1606190","article-title":"The lupus anticoagulant paradox","volume":"44","author":"Molhoek","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102470_bib3","first-page":"1065","article-title":"Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome","volume":"84","author":"Della Valle","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102470_bib4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1172\/JCI115926","article-title":"Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I","volume":"90","author":"Roubey","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rpth.2024.102470_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0038-1648480","article-title":"Lupus anticoagulant activity is frequently dependent on the presence of \u03b22-glycoprotein I","volume":"67","author":"Oostin","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102470_bib8","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"De Groot","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102470_bib10","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-11-3334","article-title":"Anti\u2013\u03b22-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome","volume":"102","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102470_bib11","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/bloodadvances.2021005205","article-title":"A\u00a0systematic review of the association between anti-\u03b2-2 glycoprotein I antibodies and APS manifestations","volume":"5","author":"Jiang","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102470_bib12","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays","volume":"16","author":"Chayoua","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102470_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102470_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20910855","article-title":"An update on the management of antiphospholipid syndrome","volume":"12","author":"Rodziewicz","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.rpth.2024.102470_bib17","first-page":"98","article-title":"Diagnosing and treating antiphospholipid syndrome: a consensus paper","volume":"77","author":"Limper","year":"2019","journal-title":"Neth J Med"},{"key":"10.1016\/j.rpth.2024.102470_bib18","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH08-04-0116","article-title":"Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon","volume":"100","author":"Beinema","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2796.1991.tb00388.x","article-title":"The effect of dietary vitamin K on warfarin-induced anticoagulation","volume":"229","author":"Pedersen","year":"1991","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.rpth.2024.102470_bib20","series-title":"WHO Expert Committee on Biological Standardization, sixty-third report","year":"1983"},{"key":"10.1016\/j.rpth.2024.102470_bib21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102470_bib22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102470_bib23","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1373\/clinchem.2016.267245","article-title":"Prolonged prothrombin time after discontinuing vitamin K antagonist","volume":"63","author":"Schellings","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2024.102470_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib25","article-title":"Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti\u2013\u03b22-glycoprotein I antibody titers","volume":"7","author":"Noordermeer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102470_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2001.03178.x","article-title":"Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins","volume":"115","author":"Tripodi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102470_bib28","first-page":"79","article-title":"Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces","volume":"59","author":"Arnout","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2024.102470_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102470_bib31","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Devreese","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/POC.0000000000000149","article-title":"Accuracy of CoaguChek XS in patients with antiphospholipid syndrome","volume":"16","author":"Taylor","year":"2017","journal-title":"Point of Care"},{"key":"10.1016\/j.rpth.2024.102470_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2022.01.021","article-title":"Warfarin monitoring and interference by lupus anticoagulant in patients with antiphospholipid syndrome","volume":"211","author":"Jepsen","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102470_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(59)90857-8","article-title":"Thrombotest a new method for controlling anticoagulant therapy","volume":"274","author":"Owren","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102470_bib35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.15241","article-title":"Anti-\u03b22-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action","volume":"19","author":"Noordermeer","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2131\/jts.28.439","article-title":"Mechanism for shortening PT and APTT in dogs and rats-effect of fibrinogen on PT and APTT","volume":"28","author":"Kurata","year":"2003","journal-title":"J\u00a0Toxicol Sci"},{"key":"10.1016\/j.rpth.2024.102470_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2006.01848.x","article-title":"Phospholipid composition controls thromboplastin sensitivity to individual clotting factors","volume":"4","author":"Smith","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","article-title":"Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference","volume":"26","author":"Okuda","year":"2004","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.rpth.2024.102470_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.1994.tb04790.x","article-title":"The role of lipids in the detection of lupus anticoagulant by the dilute Russell Viper venom test: are platelets or reagents containing hexagonal HII phases necessary?","volume":"86","author":"Stevenson","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102470_bib40","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1074\/jbc.M109.055178","article-title":"Carbohydrates and activity of natural and recombinant tissue factor","volume":"285","author":"Krudysz-Amblo","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102470_bib41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1515\/hsz-2012-0350","article-title":"Comparison of natural and recombinant tissue factor proteins: new insights","volume":"394","author":"Butenas","year":"2013","journal-title":"Biol Chem"},{"key":"10.1016\/j.rpth.2024.102470_bib42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1373\/clinchem.2010.161364","article-title":"Recombinant thromboplastins vs tissue-extract thromboplastins in patients on unstable oral anticoagulant therapy","volume":"57","author":"Remijn","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2024.102470_bib43","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1373\/clinchem.2008.111336","article-title":"Strongly increased international normalized ratio with recombinant Neoplastin R\u00ae compared with tissue extract Neoplastin Plus\u00ae in patients initiating oral anticoagulant therapy: implications for anticoagulation dosage","volume":"54","author":"Remijn","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2024.102470_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0038-1642433","article-title":"Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids","volume":"71","author":"Bader","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-2141.2001.02755.x","article-title":"Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces","volume":"113","author":"Simmelink","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102470_bib46","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1055\/s-0037-1616090","article-title":"Quantification of lupus anticoagulants in clinical samples using anti-\u03b22GP1 and anti-prothrombin monoclonal antibodies","volume":"86","author":"Le Querrec","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102470_bib47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0037-1614601","article-title":"Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human \u03b22-glycoprotein I","volume":"81","author":"Arnout","year":"1999","journal-title":"Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T10:38:57Z","timestamp":1725014337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2475037924001596"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102470","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interference of lupus anticoagulant causing antiprothrombin and anti\u2013beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized ratio methods","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102470"}}